Titan Total Current Liabilities vs Other Stockholder Equity Analysis
TTNP Stock | USD 3.88 0.08 2.02% |
Titan Pharmaceuticals financial indicator trend analysis is much more than just breaking down Titan Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Titan Pharmaceuticals is a good investment. Please check the relationship between Titan Pharmaceuticals Total Current Liabilities and its Other Stockholder Equity accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.
Total Current Liabilities vs Other Stockholder Equity
Total Current Liabilities vs Other Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Titan Pharmaceuticals Total Current Liabilities account and Other Stockholder Equity. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Titan Pharmaceuticals' Total Current Liabilities and Other Stockholder Equity is -0.58. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of Titan Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Titan Pharmaceuticals' Total Current Liabilities and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Titan Pharmaceuticals are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Total Current Liabilities i.e., Titan Pharmaceuticals' Total Current Liabilities and Other Stockholder Equity go up and down completely randomly.
Correlation Coefficient | -0.58 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Total Current Liabilities
Total Current Liabilities is an item on Titan Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Titan Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Other Stockholder Equity
Most indicators from Titan Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Titan Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.As of 12/04/2024, Sales General And Administrative To Revenue is likely to grow to 52.45, while Selling General Administrative is likely to drop slightly above 5.4 M.
Titan Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Titan Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Titan Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 9.5M | 8.1M | 8.0M | 4.1M | 8.1M | 7.7M | |
Short Long Term Debt Total | 4.4M | 809K | 299K | 187K | 565K | 536.8K | |
Other Current Liab | 1.9M | 2.3M | 1.4M | 1.5M | 519K | 493.1K | |
Total Current Liabilities | 3.6M | 4.2M | 2.7M | 2.6M | 1.4M | 1.4M | |
Total Stockholder Equity | 1.4M | 3.5M | 5.1M | 1.4M | 6.6M | 6.3M | |
Property Plant And Equipment Net | 1.2M | 759K | 717K | 407K | 68K | 64.6K | |
Net Debt | (782K) | (4.6M) | (5.7M) | (2.8M) | (6.2M) | (6.5M) | |
Retained Earnings | (349.0M) | (367.3M) | (376.1M) | (386.3M) | (391.8M) | (372.2M) | |
Accounts Payable | 1.4M | 1.3M | 795K | 695K | 348K | 330.6K | |
Cash | 5.2M | 5.4M | 6.0M | 2.9M | 6.8M | 8.3M | |
Non Current Assets Total | 1.2M | 759K | 765K | 455K | 68K | 64.6K | |
Non Currrent Assets Other | 794K | (1.2M) | (759K) | 48K | (1.0) | (0.95) | |
Cash And Short Term Investments | 5.2M | 5.4M | 6.0M | 2.9M | 6.8M | 6.4M | |
Net Receivables | 993K | 884K | 112K | 36K | 1.0M | 1.6M | |
Common Stock Shares Outstanding | 1.3K | 188.7K | 486.5K | 671.7K | 752K | 789.6K | |
Liabilities And Stockholders Equity | 9.5M | 8.1M | 8.0M | 4.1M | 8.1M | 7.7M | |
Non Current Liabilities Total | 3.8M | 4.5M | 332K | 187K | 65K | 0.0 | |
Other Stockholder Equity | 350.4M | 370.8M | 381.2M | 387.6M | 398.5M | 418.4M | |
Total Liab | 8.1M | 4.6M | 2.9M | 2.7M | 1.4M | 1.4M | |
Total Current Assets | 8.3M | 7.3M | 7.2M | 3.6M | 8.0M | 7.6M | |
Short Term Debt | 272K | 627K | 224K | 244K | 565K | 1.1M | |
Other Current Assets | 1.1M | 703K | 787K | 524K | 199K | 189.1K | |
Property Plant And Equipment Gross | 1.2M | 618K | 2.1M | 2M | 774K | 883.3K | |
Common Stock | 57K | 7K | 10K | 15K | 1K | 950.0 | |
Property Plant Equipment | 794K | 1.2M | 759K | 717K | 824.6K | 826.4K | |
Long Term Debt | 3.6M | 3.8M | 4.0M | 332K | 298.8K | 283.9K | |
Retained Earnings Total Equity | (323.3M) | (332.6M) | (349.0M) | (367.3M) | (330.6M) | (347.1M) | |
Net Tangible Assets | 6.8M | 1.4M | 3.5M | 5.1M | 4.6M | 4.7M | |
Capital Surpluse | 26.3M | 339.4M | 350.4M | 370.8M | 426.4M | 447.7M | |
Net Invested Capital | 5.5M | 4.2M | 5.1M | 1.4M | 7.1M | 4.8M |
Pair Trading with Titan Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Titan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Titan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Titan Stock
0.89 | ETON | Eton Pharmaceuticals Potential Growth | PairCorr |
0.88 | VRNA | Verona Pharma PLC | PairCorr |
0.82 | EWTX | Edgewise Therapeutics | PairCorr |
0.81 | ELDN | Eledon Pharmaceuticals | PairCorr |
0.46 | DSGN | Design Therapeutics | PairCorr |
The ability to find closely correlated positions to Titan Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Titan Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Titan Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Titan Pharmaceuticals to buy it.
The correlation of Titan Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Titan Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Titan Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Titan Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Titan Stock Analysis
When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.